Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain

Current Medical Research and Opinion

Volumn 29, Issue 10, 2013, Pages 1399-1409

  Imanaka, Keiichiro ^a   Tominaga, Yushin ^a   Etropolski, Mila ^b   Van Hove, Ilse ^c   Ohsaka, Masaki ^a   Wanibe, Mikio ^a   Hirose, Keiichiro ^a   Matsumura, Taka ^a  

^a Janssen Pharmaceutical KK   (Japan)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Analgesia; Cancer; Chronic pain; Tapentadol; Tumor

Indexed keywords

MORPHINE; OXYCODONE; TAPENTADOL;

ADULT; AGED; ARTICLE; BREAKTHROUGH PAIN; CANCER PAIN; CANCER PATIENT; CAUSE OF DEATH; CHRONIC PAIN; CONSTIPATION; CONTROLLED STUDY; DELIRIUM; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TUMOR; HUMAN; INTERSTITIAL LUNG DISEASE; JAPANESE; KOREA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDIASTINUM TUMOR; METASTASIS; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHRONIC PAIN; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PAIN MANAGEMENT; PHENOLS; REPUBLIC OF KOREA;

EID: 84884496307     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.831816     Document Type: Article

References (21)

1. Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012;13:e58-68
2. Mercadante S. Emerging drugs for cancer-related pain. Support Care Cancer 2011;19:1887-93
3. Portenoy RK. Treatment of cancer pain. Lancet 2011;377:2236-47
4. Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001;19:2542-54 (Pubitemid 32391226)
5. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician 2008;11:S105-20 (Pubitemid 351682081)
6. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182:11-18S
7. Tzschentke TM, De Vry J, Terlinden R, et al. Tapentadol hydrochloride. Analgesic, mu-opioid receptor agonist, noradrenaline reuptake inhibitor. Drugs Future 2006;31:1053-61
8. Tzschentke TM, Christoph T, Kögel B, et al. (-)-(1R, 2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel m-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007;323:265-76 (Pubitemid 47443277)
9. Lange B, Kuperwasser B, Okamoto A, et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther 2010;27:381-99
10. Keiichiro I, Koga H, Tominaga Y, et al. Study JPN-C03 was an open-label, phase 3 study to evaluate the safety and efficacy of tapentadol ER in subjects using around-the-clock opioid therapy to treat moderate to severe cancer pain (opioid-switching subjects) [abstract]. Presented at 18th Congress of the Japanese Society for Palliative Medicine, 21-22 June 2013, Yokohama, Japan
11. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9-19 (Pubitemid 40038441)
12. Farrar JT, Young Jr JP, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58 (Pubitemid 33016608)
13. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21 (Pubitemid 351147828)
14. Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of tapen-tadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo-and active-controlled phase III study. Clin Drug Investig 2010;30:489-505
15. Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo-and active-controlled Phase III study. Expert Opin Pharmacother 2010;11:1787-804
16. Wild JE, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract 2010;10:416-27
17. Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 2007;61:1181-7 (Pubitemid 46934629)
18. Candrilli SD, Davis KL, Iyer S. Impact of constipation on opioid use patterns, health care resource utilization, and costs in cancer patients on opioid therapy. J Pain Palliat Care Pharmacother 2009;23:231-41
19. Kress HG, Koch ED, Hosturski H, et al. Efficacy and safety of oral tapentadol extended release (ER) for the management of moderate to severe, chronic malignant tumor-related pain [abstract]. Presented at: the American Society of Regional Anesthesia and Pain Medicine (ASRA) 11th Annual Pain Medicine Meeting, 12-15 November 2012, Miami, Florida, USA
20. Mercadante S, Porzio G, Ferrera P, et al. Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin 2012;28:1775-9
21. Schwenke KM, Litzenburger BC. Tapentadol PR in the treatment of cancer pain in clinical practice: first data. Poster presented at: The International Association for the Study of Pain (IASP) 14th World Congress on Pain, 27-31 August 2012, Milan, Italy